HEPA Hepion Pharmaceuticals, Inc. Insider Trading

Insider accumulates 6.25M shares at depressed valuation while stock trades near 52-week lows amid unprofitable operations.

An insider has made substantial open-market purchases of over six million shares in Hepion Pharmaceuticals, adding to existing holdings at a time when the stock is trading dramatically below its recent highs and has lost significant value over recent months. The company is burning cash with no revenue and ongoing quarterly losses, indicating it remains in a development or distressed phase. This is a classic knife-catching scenario where an insider is betting on either a strategic inflection, clinical trial milestone, or acquisition despite severe financial headwinds. The conviction signal is meaningful—the insider is putting real capital to work and increasing exposure by a quarter of their holdings—but the fundamental weakness and extreme stock underperformance raise questions about whether this is contrarian conviction or capitulation into insolvency risk.

Insider purchases 1.25M shares of HEPA at distressed valuation amid severe stock decline and ongoing losses

An insider has purchased over a million shares of Hepion Pharmaceuticals at a depressed price, signaling belief in a potential turnaround despite the company's dire financial condition. The stock has collapsed significantly from its recent highs and is trading near multi-year lows, suggesting either capitulation selling or a contrarian accumulation opportunity. Fundamentally, Hepion is unprofitable with zero revenue and substantial quarterly losses, indicating the company is in a pre-commercial or failed development stage burning through cash. This insider buy at rock-bottom levels could represent either conviction in hidden value or an attempt to prop up a struggling asset—the distinction matters significantly for investors. Without visibility into the insider's historical track record or upcoming catalysts (clinical trials, partnerships, etc.), this trade warrants close monitoring to determine whether this represents savvy bottom-fishing or a warning sign of desperation.

Interim CEO Gary S. Stetz buys 1,250,000 shares of HEPA at $0.04; 3 other insiders bought within 14 days

Gary S. Stetz, serving as Interim CEO, purchased 1,250,000 shares at $0.04 on 2026-04-21, representing his first shareholding position in Hepion Pharmaceuticals. This transaction is part of a broader cluster pattern: 3 other insiders also executed purchases within the past 14 days, suggesting coordinated or coincident accumulation activity across the leadership group. The buy occurs at a price substantially below the 52-week high of $0.39, with Hepion currently trading at $0.06 (a level 30% above the transaction price), though the stock remains deeply depressed relative to its year-ago range. The company faces fundamental headwinds: zero revenue in the latest quarter, cumulative net losses of $-472,506.00 in the most recent full fiscal year, and a market capitalization of only $697,219.02, indicating an unprofitable, pre-revenue or minimal-revenue stage biotech. The convergence of multiple insider purchases at a distressed valuation warrants examination of whether this reflects planned capital needs, leadership commitment amid operational stress, or other drivers that should be factored into investment risk assessment.

Director Michael J. Purcell purchases 1,250,000 shares of HEPA at $0.04; cluster pattern with 3 other insiders buying in past 14 days.

Director Michael J. Purcell acquired 1,250,000 shares at $0.04 on 2026-04-21, with a post-transaction holding of 1,250,000 shares (zero prior position). This buy occurs within a cluster pattern: 3 other insiders also purchased within the past 14 days, suggesting coordinated or simultaneous conviction at the $0.04 price level. The company is materially distressed—latest quarterly revenue was $0.00, net income was $-472,506.00, and market cap stands at only $697,219.02—yet the multi-insider purchase activity signals potential board-level or management alignment at depressed valuations. The stock trades at $0.06 currently, 50% above the transaction price, though it remains -84.6% from its 52-week high of $0.39, indicating severe deterioration from prior levels.